Oltean, Sebastian
Dr
所属大学: University of Bristol
所属学院: School of Physiology, Pharmacology and Neuroscience
邮箱:
sebastian.oltean@bristol.ac.uk
个人主页:
http://www.bristol.ac.uk/phys-pharm/people/sebastian-oltean/overview.html
近期论文
Mavrou, A, Brakspear, K, Hamdollah-Zadeh, M, Damodaran, G, Babaei-Jadidi, R, Oxley, J, Gillatt, DA, Ladomery, MR, Harper, SJ, Bates, DO & Oltean, S, 2015, ‘Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer’. Oncogene. Oltean, S & Bates, DO, 2014, ‘Hallmarks of alternative splicing in cancer’. Oncogene, vol 33., pp. 5311-5318 Oltean, S, Sorg, B, Albrecht, T, Bonano, V, Brazas, R, Dewhirst, M & Garcia-Blanco, M, 2006, ‘Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity’. PNAS. Amin, E, Oltean, S, Hua, J, Gammons, M, Hamdollah-Zadeh, A, Welsh, G, Cheung, M, Ni, L, Kase, S, Rennel, E, Symonds, K, Nowak, D, Royer-Pokora, B, Saleem, M, Hagiwara, M, Schumacher, V, Harper, S, Hinton, D, Bates, D & Ladomery, M, 2011, ‘WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing’. Cancer Cell, vol 20., pp. 768 - 780 Bonano, V, Oltean, S & Garcia-Blanco, M, 2007, ‘A protocol for imaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice’. Nature Protocols. Mavrou, A & Oltean, S, 2016, ‘SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing’. Pharmacological Research, vol 107., pp. 276-281 Bullock, N, Potts, J, Simpkin, AJ, Koupparis, A, Harper, SJ, Oxley, J & Oltean, S, 2016, ‘Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion’. Molecular Pathology, vol 69., pp. 171-5 Stevens, M & Oltean, S, 2016, ‘Alternative Splicing in CKD’. Journal of the American Society of Nephrology. Oltean, S, Qiu, Y, Ferguson, JK, Stevens, M, Neal, C, Russell, A, Kaura, A, Arkill, KP, Harris, K, Symonds, C, Lacey, K, Wijeyaratne, L, Gammons, M, Wylie, E, Hulse, RP, Alsop, C, Cope, G, Damodaran, G, Betteridge, KB, Ramnath, R, Satchell, SC, Foster, RR, Ballmer-Hofer, K, Donaldson, LF, Barratt, J, Baelde, HJ, Harper, SJ, Bates, DO & Salmon, AHJ, 2015, ‘Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy’. Journal of the American Society of Nephrology, vol 26., pp. 1889-904 Bunni, J, Shelley-Fraser, G, Stevenson, K, Oltean, S, Salmon, A, Harper, SJ, Carter, JG & Bates, DO, 2015, ‘Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios’. American Journal of Cancer Research, vol 5., pp. 2083-9